Physician profile
Rishell Tsujimoto-Ryzewski
NPI 1558603118
$1,052.47
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $112 · 2021: $357 · 2022: $449.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.84 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $227.98 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.49 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.37 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $59.90 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $59.35 | 2020-2021 | |
| Eisai INC. | $56.11 | 2021 | |
| Vanda Pharmaceuticals INC. | $46.08 | 2022 | |
| Lundbeck LLC | $43.30 | 2021 | |
| Merck Sharp & Dohme LLC | $33.70 | 2022 | |
| Bausch Health US, LLC | $21.61 | 2022 | |
| Alkermes, INC. | $21.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2021 | |
| Neurocrine Biosciences, INC. | $13.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishell Tsujimoto-Ryzewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.